Incredibly proud of this work. We detail the evolution of liver-secreted and plasma proteins with MASLD progression, providing a rich resource defining human hepatokines and a predictive model that stratifies MASH. @will_denardo @UniMelbMDHS https://t.co/zOthpBflhw
Lovely Promethion-powered science from @briandrew101 & colleagues @MonashUni - imbalanced folate intermediates may be a previously unrecognized pathology linking the mitochondrial integrated stress response & mitochondrial disease! https://t.co/wzmVkxJwPV
We could reduce the severity of heart failure and other conditions in mitochondrial disease patients by trying to stop cells dying and organs failing. Sadly, many people with mitochondrial disease currently don’t survive past 20 or 30 years of age.
https://t.co/SZDvtE9VsB
Happy to share the final version of our new paper published in @NatureComms describing a novel inducible, tissue specific #PolG mutation mouse model, that provides interesting insights into muscle specific #mitochondria induced stress responses
https://t.co/ndOUy6TJKs
Happy to share the final version of our new paper published in @NatureComms describing a novel inducible, tissue specific #PolG mutation mouse model, that provides interesting insights into muscle specific #mitochondria induced stress responses
https://t.co/8PUo8bhgPK
🚨 Exciting News! 🚨@heartfoundation 2025 research funding opportunities are now open! As a past recipient of the Vanguard Grant, I encourage you to apply and drive innovation in cardiovascular health.
🔗Explore the opportunities
#HeartFoundation#CardiovascularHealth
Very grateful to receive a Heart Foundation Vanguard grant with @briandrew101@FebbraioMark
Thank you @heartfoundation for supporting our research using a new model of heart failure and cardiac hepatopathy, which will enable us to explore the mechanisms driving these conditions
Thanks to the @heartfoundation for supporting our labs research @BakerResearchAu led by Simon Bond and collaborators @FebbraioMark
https://t.co/rP4Cz41PKK
Excited to start this work on cardiac hepatopathy, and trying to understand the mechanisms driving this condition
Rebuilding the ♥️ after a #heartattack, using #mRNA therapy to prevent #bloodclots & using ultrasound to provide a window into #AF in people with #diabetes. These are some of the projects our scientists will undertake thanks to @heartfoundation funding👏
https://t.co/KOhVwAbZGl
Super proud of this team effort published in @JACCJournals We wanted to highlight the importance of considering the effects of #cancer treatment beyond the #heart
Cancer Therapy and Exercise Intolerance: The Heart Is but a Part: JACC... https://t.co/ylGYKRk5aj
Skeletal Muscle Specific PolG Dysfunction Activates the Integrated Stress Response and Promotes a Cachexia like Phenotype https://t.co/Jc99NEW16y #biorxiv_physio
Super excited to release our latest work in @biorxivpreprint on #PolG, #mitochondria and skeletal #muscle. This study led by @Simon23206236 and @Eking_Sci describes a novel conditional PolG model that allows for tissue specific alterations in #mtDNA integrity 🧵 /1
So excited to win the @MonashCCS round of the 3MT competition today! Congratulations to everybody who presented, it was so interesting to hear all the projects going on across the school.
Lots happening in the #systems#genetics field of late with unique #multiomics platforms being published. In our latest review in @eLife we discuss approaches involving integration of cross species data to improve understanding.
https://t.co/BjEV12O5QN
BEYOND ELATED to have this published @NatureCVR - We show only ♀️ mice lacking #Estrogen Receptor α specifically in 🫀develop #obesity due cardiac metabolic dysregulation & release of cardiac #EVs that remodelled adipose & sk mus tissues
#CardioTwitter
https://t.co/vmOKzOY4SG
💚We are hiring! 🎉Mito Foundation is seeking an organised all-rounder Communications Officer hoping to gain experience in the not- for-profit space and make meaningful change for people impacted by mito.
https://t.co/y2VonM1joN
#job#charity#support#sydney
New work from the lab, superbly led by @DevereuxCamille. Investigating dual inhibition of ACC and CD36 for the treatment of non-alcoholic fatty liver disease in mice. @AJPEndoMetab#metabolism#NAFLD https://t.co/1PuWWNYsoT